CORONA Remedies Limited
(Formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House
C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059. Gujarat, India.
Tele.: +079 - 40233000
Online at : Info@coronaremedies.com
website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

July 31, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (East), Mumbai - 400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Unaudited Financial Results of the Company for Q1FY27 and three months ended June 30, 2026.

The press release is also being made available on the website of the Company at www.coronaremedies.com

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

CHETNA PRABHAT KUMAR DHARAJIYA

Digitally signed by CHETNA PRABHAT KUMAR DHARAJIYA
Date: 2026.07.31 17:11:43 +05'30'

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

PRESS RELEASE

CORONA Remedies delivers a strong start to FY 27, with a **Revenue growth of 21.9% and a PAT growth of 30.1%** Y-o-Y for Q1FY27, driven by robust Brand Building and Operational Excellence

Ahmedabad | July 31, 2026

CORONA Remedies Limited, a leading India-focused branded pharmaceutical company, announced its unaudited financial results for Q1FY27, delivering robust revenue and resilient margins, supported by **consistent brand-building, focus on engine brands and enhanced operational efficiencies**.

Key Operational & Financial Highlights

- Delivered ₹ 422.4 Cr revenue for Q1FY27 registering a **growth of 21.9% Y-o-Y** supported by execution excellence and focused brand building initiatives.
- PAT for Q1FY27 stood at ₹ 60.1Cr, **a growth of 30.1% Y-o-Y**. PAT margins for Q1FY27 stood at 14.2%, an increase of **90 bps Y-o-Y.**

Financial Performance Snapshot:

Particulars (₹ in Cr)	Q1FY27	Q1FY26	Y-o-Y % Growth
Revenue from Operations	422.4	346.5	**21.9%**
EBITDA	93.1	69.8	**33.5%**
EBITDA Margin	22.0%	20.1%	**190 bps**
Profit After Tax	60.1	46.2	**30.1%**
Profit After Tax Margin	14.2%	13.3%	**90 bps**

Key Business Highlights:

- **Outpacing IPM Growth[1]:** CORONA continues to be the **fastest growing** company among top 30 companies of IPM **for last 6 consecutive months,** as per MAT June'26. CORONA has outperformed market **by 1.9 times** as per MAT June'26.

- **Market Rank Progression[1]:** Rank moves **3 places up** in a year and reaches at **26th Rank** as per MAT June'26 and for the quarter (We were at 29th Rank as of MAT June'25).

- **Therapy Leadership[1]**: CORONA stands at **5th rank in Gynaecology**; reflecting our commitment and therapy leadership in the segment.

- **Inauguration of Female Hormone Plant:** Inaugurated and initiated the commercialization of our EU-GMP approved Female Hormone Manufacturing Facility based in Ahmedabad, on **30 June 2026**.

- **Integration of Wokadine** (acquired brand): We have initiated the smooth integration of Wokadine from the supply side and distribution perspective.

[1]: As per Pharmatrac June'26 Data

Commenting on the performance for Q1FY27, **Mr. Nirav K. Mehta, Managing Director & CEO,** CORONA Remedies Limited, said:

"Q1 FY27 shows our commitment to consistent growth with operational excellence and brand building. With robust revenue growth and market rank improvement, we see positive outcomes of the strategies in place.

We aim to move steadfast with our aligned focus on core therapies such as Women's Healthcare, Cardio-diabetes, Pain Management and Urology. We are also strengthening ourselves in Infertility and Biosimilar segment."

About CORONA Remedies Limited

Founded in 2004, CORONA Remedies Limited is a leading India-focused pharmaceutical company engaged in developing, manufacturing, and marketing products across key therapeutic areas including women's healthcare, cardio-diabetes, pain management and urology.

The company operates WHO-GMP/EU GMP-certified manufacturing facilities and maintains strong innovation capabilities through DSIR-approved R&D centers.

For further information, please contact

Company	Investor Relations Advisors
CORONA Remedies Limited CIN: L24231GJ2004PLC044656 Chetna Dharajiya – Company Secretary & Compliance Officer	**Strategic Growth Advisors Pvt Ltd.** CIN: U74140MH2010PTC204285 Sagar Shroff / Tanay Shah Email id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899